Golvatinib/Lenvatinib

N/A

Report date: 2024/04/07 16:54:43

Base Information

Drug NameGolvatinib/Lenvatinib
Drug Alias Namegolvatinib + lenvatinib (glioblastoma/melanoma/vascular cancers), Eisailenvatinib + golvatinib (melanoma/glioblastoma), EisaiE-7050 + E-7080 (melanoma/glioblastoma), EisaiLenvatinib Mesylate/Golvatinib tartrateLenvatinib Mesylate+Golvatinib tartrate +[10] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionFibroblast growth factor receptor 4 antagonistsHepatocyte growth factor receptor inhibitorsFibroblast growth factor receptor 3 antagonists +[11] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[11] 
Therapy Area/IndicationsAngiomatosisMelanomaGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Golvatinib tartrateLenvatinib Mesilate
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEisai Co Ltd
Active IndicationsN/A
Inactive IndicationsAngiomatosisMelanomaGlioblastoma

Other Information

ATC CodeN/A
Related LinksN/A